J. Zou

发表

Pyrotinib plus capecitabine for human epidermal growth factor receptor 2-positive metastatic breast cancer after trastuzumab and taxanes (PHENIX): a randomized, double-blind, placebo-controlled phase 3 study

H. Yao, Yongmei Yin, Zefei Jiang, 2020 .

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.

Ying Cheng, Jian-hua Chang, Yunpeng Liu, 2020, The Lancet. Respiratory medicine.

Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: A randomized, double‐blind, placebo‐controlled, phase 3 trial

G. Qin, Zi-lin Sun, Liujun Fu, 2021, Diabetes, obesity & metabolism.

Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.

Lifeng Wang, Yong Fang, Haihua Yang, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Title: Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Yang Luo, Bing-he Xu, D. Zhong, 2019 .

Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial

T. Chong, X. Qin, D. Ji, 2022, BMC Medicine.

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Ming Yan, Yongmei Yin, Bing-he Xu, 2021, Nature Medicine.

Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial

Xin Hu, L. Fan, Junjie Li, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study

Ying Cheng, Yi-long Wu, Jin-Ji Yang, 2021, Cancer Immunology, Immunotherapy.

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.

Jianxing He, Y. Shu, Yiping Zhang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study.

H. Yao, Yongmei Yin, Zefei Jiang, 2019, Journal of Clinical Oncology.

Camrelizumab plus oxaliplatin‐based chemotherapy as first‐line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial

Z. Meng, Z. Ren, S. Qin, 2021, International journal of cancer.

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Jianji Pan, W. Feng, Xiaozhong Chen, 2021, Journal for ImmunoTherapy of Cancer.

Henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial

P. Li, Liujun Fu, L. Zeng, 2021, Diabetes, obesity & metabolism.

First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SHR2285, a Small-Molecule Factor XIa Inhibitor in Healthy Subjects

Shuyang Zhang, P. Hu, J. Zou, 2022, Frontiers in Pharmacology.

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

Li Yan, Yanhua Ding, Junyan Wu, 2022, BMC Medicine.

DDDT_A_304857 1873..1882

Z. Meng, Z. Ren, S. Qin, 2021 .

A Phase 1 Study of SHR6390, A Cyclin-dependent Kinase 4/6 Inhibitor in Patients with Advanced Breast Cancer

Wen-na Wang, Bing-he Xu, Xiaoyu Zhu, 2020 .

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.

Y. Ba, Jianming Xu, He-long Zhang, 2020, The Lancet. Oncology.

Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous non-small-cell lung cancer (CameL-sq): a phase 3 trial.

Ying Cheng, R. Guo, Yiping Zhang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Semi-Mechanistic Modeling of HY-021068 Based on Irreversible Inhibition of Thromboxane Synthetase

Ping Li, Guoping Yang, Jie Huang, 2020, Frontiers in Pharmacology.

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.

Ying Cheng, Yongmei Yin, Bing-he Xu, 2021, The Lancet. Oncology.

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Tao Zhang, Wei Shi, Jian-hua Chang, 2022, Cancer communications.

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia

Jing Liu, Jie Jin, Jianda Hu, 2021, Journal of Hematology & Oncology.

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

Ying Cheng, Y. Ba, Dong Wang, 2021, JAMA.

A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

Wen-na Wang, Bing-he Xu, Xiaoyu Zhu, 2021, Biomarker Research.

Pyrotinib combined with CDK4/6 inhibitor in HER2‐positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients

Yingying Xu, L. Shen, Zuhua Chen, 2020, Clinical and translational medicine.

Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

Peng Yuan, Jiayu Wang, Qiao Li, 2019, Clinical Cancer Research.

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial

Ying Cheng, R. Guo, Sheng Hu, 2022, Molecular cancer.

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.

W. Feng, Xiaozhong Chen, Jinsheng Hong, 2021, The Lancet. Oncology.

Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial

G. Lou, Y. Meng, Junying Tang, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study

X. Yi, Zhiyuan Hu, Jianming Xu, 2018, Clinical Cancer Research.

Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study

Jing Liu, Depei Wu, Yu Hu, 2021, Annals of translational medicine.

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

W. Fang, Xinchen Sun, E. Li, 2020, Journal of Hematology & Oncology.

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.

W. Fang, E. Li, Z. Meng, 2020, The Lancet. Oncology.

Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.

Ying Cheng, Jia Wei, L. Shen, 2019, Journal of Clinical Oncology.

A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment.

W. Fang, Y. Xia, E. Li, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Xin Hu, L. Fan, Z. Shao, 2022, Molecular cancer.

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Xin Hu, C. Verschraegen, Z. Shao, 2020, Cell Research.

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Ying Cheng, W. Fang, Jianming Xu, 2021, The lancet. Gastroenterology & hepatology.

Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Ying Cheng, Jia Wei, L. Shen, 2021, Clinical Cancer Research.

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial

Jin-hai Tang, Zefei Jiang, Xiaoyu Zhu, 2022, BMC Medicine.

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Xin Hu, Z. Shao, Xiaoyu Zhu, 2020, Cell Research.

Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Y. Liu, S. Qin, Zhendong Chen, 2021, Journal for ImmunoTherapy of Cancer.

Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.

Wei Li, Shiying Yu, Quchang Ouyang, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.

Ying Cheng, Yongmei Yin, Bing-he Xu, 2020 .

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study

R. Xu, Xiaotian Zhang, J. Gong, 2023, Cancer medicine.

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Study

R. Guo, Yiping Zhang, Wei Zhang, 2022 .

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

A. Nagrial, M. Millward, P. Grimison, 2020, Drug design, development and therapy.

A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

W. Fang, E. Li, Z. Meng, 2021, Liver Cancer.

A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Z. Meng, Z. Ren, S. Qin, 2019, Journal of Clinical Oncology.

Characterization and quantitative determination of henagliflozin metabolites in humans.

D. Zhong, Yifan Zhang, Yan Zhan, 2020, Journal of pharmaceutical and biomedical analysis.

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

Xin Hu, L. Fan, Keda Yu, 2021 .

Abstract PD8-08: Pyrotinib in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer (PHEDRA): A randomized, double-blind, multicenter, phase 3 study

Jin-hai Tang, Chuan Wang, Jiong Wu, 2022, Cancer Research.

Pulmonary blastoma treatment response to anti-PD-1 therapy: a rare case report and literature review

J. Zou, Yalin Xie, N. Su, 2023, Frontiers in Oncology.

Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation.

Jianxing He, Y. Shu, Yiping Zhang, 2019, Journal of Clinical Oncology.

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

R. Xu, Yiping Zhang, Q. Fan, 2021, Journal of Clinical Oncology.

Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial.

Jianming Xu, Quanren Wang, R. Jia, 2018 .

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Z. Meng, Z. Ren, S. Qin, 2021, Drug design, development and therapy.

Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.

Qing Yang, Chaosu Hu, Li Zhang, 2021 .

Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer

Ming Yan, Ying Cheng, Yongmei Yin, 2022, Cancer Research.

SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study.

Qi Zhou, Yuping Sun, Yunlang Cai, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Ning Zhang, W. Dang, Zhihong Wang, 2022, Therapeutic Advances in Musculoskeletal Disease.

Dynamics of Acquired Resistance to Nivolumab Therapies Varies From Administration Strategies.

Chenrong Huang, Xiaoquan Liu, S. Zheng, 2021, Clinical therapeutics.

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Lianshan, P. Grimison, A. Behren, 2020 .

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial.

Jun Zhu, S. Hao, Kunyan Li, 2022, The Lancet. Haematology.